Meipude Biotechnology

Meipude Biotechnology is an innovative drug discovery company headquartered in Beijing that specializes in structural biology and AI-driven drug design. The company focuses on developing small molecule therapies for challenging protein-protein interaction (PPI) targets and membrane proteins that have historically been considered "undruggable." By integrating cryo-electron microscopy (Cryo-EM), high-throughput screening, and proprietary AI algorithms, Meipude aims to accelerate the discovery of high-affinity leads for oncology and immunology. Their current pipeline features programs targeting the RAS/MAPK signaling pathway, including SOS1 and SHP2 inhibitors. Meipude operates through a combination of internal drug development and strategic partnerships with global pharmaceutical entities.